High program completion rates81% of members finishing the first year and 70% enrolling in a secondfurther support its effectiveness for motivated individuals
What remains most novel about GLP-1 medications is that they target underlying biological drivers of energy intake and metabolic regulationfactors closely tied to chronic disease riskrather than simply promoting short-term weight reduction, and may, in the long run, contribute to lower health insurance costs by treating related comorbidities, even as they may impact patient longevity and, thus, how life insurance treats these drugs
United States takes the 51% of the fund, followed by Denmark (18%) and Japan (10%).
Disclosures: I own shares in Eli Lilly and Lir Life Sciences
External resources American Journal of Clinical Nutrition: Nutritional priorities to support GLP-1 therapy for obesity Endocrine Society: Protein may protect against muscle loss on semaglutide (ENDO 2025) Impact of semaglutide on body composition in adults with overweight or obesity: STEP 1 study For researchers serious about optimizing their peptide protocols and nutrition strategies during GLP-1 therapy, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, proven protocols, personalized calculators, and a community of thousands who have navigated these exact questions
Dose Adjustments: Renal Insufficiency: Patients with severe kidney disease require very close monitoring